TREVENTIS

TREVENTIS is dedicated to the treatment and prevention of protein misfolding diseases. The company's leading program focuses on anti-misfolding small molecules in taupath (3R, 4R, familial mutations, and mixed) associated with Alzheimer's disease. Further CCM-driven efforts in oncology and other neurodegenerative diseases demonstrate the broad applicability of our technology platform.